A macrophage-derived factor induced by α1-acid glycoprotein that inhibits IL-1 comitogenic activity

Genetic study of orosomucoid by isoelectric focusing and immunoprinting in patients with carcinoma

“…The ORMl gene is localized on chromosome 9q31.. .34.1 near the loci of ABO and adenylate kinase 1 [9]. While the pteridine-containing ORM variant seems to correlate with malignant diseases [2,3], there is also evidence that genetic variations of ORM may influence oncogenesis [12]. Therefore we investigated the phenotypical distribution of the ORMl subtypes in patients with carcinomas.…”

Apotransferrin, C1‐esterase inhibitor, and alpha 1‐acid glycoprotein for cerebral protection during experimental hypothermic circulatory arrest

“…Its biological function is not completely known. AGP has been demonstrated to have anti-inflammatory properties such as inhibition of neutrophil activation, inhibition of platelet aggregation, inhibition of superoxide generation, induction of macrophage-derived interleukin-1 receptor antagonist release, reduction of complement activation, inhibition of apoptosis, protection against oxidative stress, stabilization of erythrocyte membranes, and facilitation of the passage of erythrocytes through the capillaries (18)(19)(20)(21)(22).…”

α1-Acid glycoprotein induced effects in rat brain microvessel endothelial cells

“…AGP has been reported to have anti-inflammatory, immunomodulatory and vascular protective roles suggesting a role as a biomarker of inflammatory diseases (Curry et al, 1989; Jorgensen et al, 1998; Pukhal’skii et al, 2000; Ceciliani et al, 2007). AGP acts on immune cells that are involved in the inflammatory process, such as decreasing thymocyte proliferation via macrophage derived IL-1 inhibitor (Bories et al, 1990), and modulating lymphocyte proliferation as well as regulate cytokine (IL-1, IL-2, IL-6, and TNF-α) production by leukocytes via mitogen activators (Shiyan and Bovin, 1997). Reducing reactive oxygen species production by neutrophils upon phorbol 12-myristate 13-acetate (PMA) stimulation (Stakauskas et al, 2005) and changing the shape of platelets via Rho/Rho-kinase signaling pathway (Gunnarsson et al, 2009) are also biological characteristics of AGP.…”

“…There is evidence for cross-talk between APPs and pro-inflammatory cytokines like IL-1, IL-6 and TNF-α, which are known to stimulate hepatocytes to increase the expression of AGP and other positive APPs during inflammation (Castell et al, 1989; Christian Pous, 1989; Baumann and Gauldie, 1990). Bories et al showed that AGP can inhibit IL-1 activity by modulating an unknown macrophage derived factor (Bories et al, 1990). While AGP is primarily produced by hepatocytes, it is also produced by endothelial cells where it plays an important role in forming the glycocalyx (Curry et al, 1989; Sorensson et al, 1999).…”